PARATEK PHARMACEUTICALS INC's ticker is and the CUSIP is 699374AB0. A total of 19 filers reported holding PARATEK PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $34,151,524 | +105270.2% | 34,893,000 | -13.3% | 1.50% | +26.3% |
| Q1 2023 | $32,411 | -3.8% | 40,262,000 | +11.1% | 1.19% | +28.4% |
| Q4 2022 | $33,698 | -99.9% | 36,234,000 | 0.0% | 0.93% | +103.5% |
| Q3 2022 | $32,473,000 | -2.7% | 36,234,000 | 0.0% | 0.46% | -40.0% |
| Q2 2022 | $33,372,000 | +4.5% | 36,234,000 | +1.7% | 0.76% | +2.3% |
| Q1 2022 | $31,948,000 | -1.2% | 35,615,000 | 0.0% | 0.74% | +5.2% |
| Q4 2021 | $32,321,000 | -25.9% | 35,615,000 | -29.2% | 0.71% | -38.8% |
| Q3 2021 | $43,615,000 | -4.9% | 50,277,000 | +2.9% | 1.15% | -9.3% |
| Q2 2021 | $45,855,000 | +17.1% | 48,847,000 | +9.8% | 1.27% | -18.5% |
| Q1 2021 | $39,153,000 | +12.2% | 44,492,000 | +12.9% | 1.56% | +16.7% |
| Q4 2020 | $34,911,000 | +33.2% | 39,392,000 | +25.1% | 1.34% | -5.4% |
| Q3 2020 | $26,208,000 | +12.1% | 31,481,000 | +6.4% | 1.41% | -29.0% |
| Q2 2020 | $23,376,000 | -1.7% | 29,590,000 | -18.7% | 1.99% | -21.9% |
| Q1 2020 | $23,790,000 | -12.9% | 36,390,000 | -3.8% | 2.55% | -15.7% |
| Q4 2019 | $27,328,000 | +5.6% | 37,825,000 | 0.0% | 3.02% | -20.0% |
| Q3 2019 | $25,876,000 | -11.3% | 37,825,000 | -8.5% | 3.78% | +95.9% |
| Q2 2019 | $29,160,000 | – | 41,325,000 | – | 1.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cohanzick Management, LLC | 25,112,000 | $25,557,982 | 22.10% |
| Westchester Capital Management, LLC | 8,267,000 | $8,308,536 | 0.24% |
| MACQUARIE GROUP LTD | 5,359,000 | $5,386,000 | 0.01% |